Skip to content
Zerafil Dosing
Response Assessment
Response Assessment: Asthma
Response Assessment: Urticaria
Response Assessment: CRSwNP
Treatment Initiation
Treatment Initiation: Asthma
Treatment Initiation: Urticaria
Treatment Initiation: CRSwNP
Control Test
Control Test: Asthma (ACT)
Control Test: Urticaria (UCT)
Control Test: Sino-Nasal Outcome Test (SNOT-22)
Zerafil Dosing
Response Assessment
Response Assessment: Asthma
Response Assessment: Urticaria
Response Assessment: CRSwNP
Treatment Initiation
Treatment Initiation: Asthma
Treatment Initiation: Urticaria
Treatment Initiation: CRSwNP
Control Test
Control Test: Asthma (ACT)
Control Test: Urticaria (UCT)
Control Test: Sino-Nasal Outcome Test (SNOT-22)
Contact us
Treatment Initiation: CRSwNP
Is the patient’s disease adequately controlled with the current treatment?
Yes
No
Has the patient received saline nasal irrigation and intranasal corticosteroids (INCS) for 3–6 months?
Yes
No
INCS: intranasal corticosteroids
Has the patient received oral corticosteroids (OCS) for 10–14 days?
Yes
No
OCS: oral corticosteroids
Which of the following applies to this patient?
Contraindication to surgery.
Patient’s resistance to surgery.
Poorly controlled asthma.
Hidden
sum Q4
Which of the following criteria apply to this patient?
(Required)
Evidence of type 2 inflammation. (Tissue eos ≥ 10/hpf, OR blood eos ≥ 150, OR total IgE ≥ 100)
Need for systemic corticosteroid or contraindication to systemic steroids. (≥ 2 courses per year, OR long-term(> 3 months) low-dose steroids)
Significantly impaired quality of life. (SNOT-22 ≥ 40)
Significant loss of smell.
Diagnosis of comorbid asthma. (Asthma needing regular inhaled corticosteroids)
eos: eosinophil , hpf: high power field (×400) , SNOT-22: sino-nasal outcome test-22
Hidden
sum Q5
The patient is considered a candidate for surgery. Is the patient considered refractory to surgery?
Yes
No
Overview of the Algorithms
